Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney

Current Medical Research and Opinion

Volumn 27, Issue 2, 2011, Pages 383-391

  Grima, Daniel T ^a   Airia, Parisa ^a   Attard, Cheryl ^a   Hutchison, Colin A ^b,c  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cast nephropathy; Cost effectiveness; Dialysis; Multiple myeloma; Renal failure

Indexed keywords

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MATHEMATICAL MODEL; MULTIPLE MYELOMA; QUALITY OF LIFE;

ALGORITHMS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; LIFE EXPECTANCY; MODELS, ECONOMIC; MULTIPLE MYELOMA; QUALITY OF LIFE; RECOVERY OF FUNCTION; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 78651395308     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.543125     Document Type: Article

References (34)

1. Alexander DD, Mink PJ, Adami H, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007;120(Suppl. 12):40-61 (Pubitemid 46766474)
2. BladéJ, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-93
3. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65:175-81
4. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogen-esis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999;13:79-90
5. Torra R, BladéJ, Cases AL, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995;91:854-9
6. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure. Ann Intern Med 2005;143:777
7. Lee C, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33:823-8
8. Rayner HC, Haynes AP, Thompson JR, et al. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med 1991;79:517-25
9. Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. Q J Med 1997;90:773-80
10. Magee C, Vella JP, Tormey WP, et al. Multiple myeloma and renal failure: one center's experience. Renal Failure 1998;20:597-606
11. Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998;13:1438-45
12. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of borte-zomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6
13. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009;9:302-6
14. Innes A, Cuthbert RJ, Russell NH, et al. Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol 1994;16:149-56
15. Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine 1987;66:126-37
16. Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2009;25:419-26
17. Cserti C, Haspel R, Stowell C, et al. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007;47:511-14
18. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-95
19. Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney International 1988;33:1175-80
20. Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-9
21. Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-54
22. Hutchison C, Airia P, Cook M, et al. Improving outcomes in patients with renal failure secondary to multiple myeloma: results from ChAR2M2. In: Blood (ASH Annual Meeting Abstracts). 2009 p. 1875
23. Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008;9:55
24. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal, 2008. Available at: http://www.nice.org.uk/media/B52/ A7/TAMethodsGuideUpdatedJune2008.pdf [Last accessed date 23 July 2009]
25. Weibull W. A statistical distribution function of wide applicability. J Appl Mech Trans ASMA 1951;18:293-7
26. UK Department of Health. NHS Costing Manual 2007-2008. 2008. Available at: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/ documents/digitalasset/dh-082745.pdf [Last accessed date 23 July 2009]
27. Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluation. In: Drummond W, McGuire A (eds). Economic Evaluation in Health Care: Merging Theory with Practice. Oxford, UK: Oxford University Press, 2001
28. Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press, 2001
29. Luce B, Manning W, Siegel J, et al. Estimating costs in cost-effectiveness analysis. In: Gold M, Siegel J, Russell L, Weinstein M (eds). Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness. New York, USA: Oxford University Press, 1996
30. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31
31. Drummond M, Sculpher G, Torrance B, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford, UK: Oxford University Press, 2005
32. Canadian Agency for Drugs and Technologies in Health. CADTH 2006. Guidelines for the Economic Evaluation of Health Technologies, 3rd edn. Canada, 2006. Available at: http://www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf [Last accessed date 20 July 2009]
33. Van Agthoven M, Segeren CM, Buijt I, et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by mye-loablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study. Eur J Cancer 2004;40:1159-69
34. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney International 2005;68:2801-8